Loading...
XETR
BNN
Market cap53mUSD
May 07, Last price  
2.16EUR
1D
3.85%
1Q
-24.74%
Jan 2017
-87.34%
IPO
-77.05%
Name

BRAIN Biotech AG

Chart & Performance

D1W1MN
P/E
—
P/S
0.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.89%
Rev. gr., 5y
7.22%
Revenues
55m
-1.27%
7,476,28510,134,51112,987,60821,132,36322,789,95024,105,00027,051,00038,560,00038,225,00038,389,00049,509,00055,335,00054,631,000
Net income
-11m
L+34.40%
-5,537,256-4,095,361-5,044,485-5,714,554-14,689,820-9,607,000-8,276,000-10,495,000-9,017,000-4,679,000-6,341,000-8,279,000-11,127,000
CFO
-4m
L-15.05%
-5,886,002-4,849,068-3,903,265-4,113,241-8,683,489-5,757,000-5,418,000-3,380,000-4,767,000-3,906,000-1,485,000-4,218,000-3,583,000
Earnings
May 26, 2025

Profile

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.
URL
https://www.brain-biotech.de/
IPO date
Feb 09, 2016
Employees
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
54,631
-1.27%
55,335
11.77%
49,509
28.97%
Cost of revenue
29,277
62,226
31,229
Unusual Expense (Income)
NOPBT
25,354
(6,891)
18,280
NOPBT Margin
46.41%
36.92%
Operating Taxes
111
625
176
Tax Rate
0.44%
0.96%
NOPAT
25,243
(7,516)
18,104
Net income
(11,127)
34.40%
(8,279)
30.56%
(6,341)
35.52%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
8,651
4,659
3,037
Long-term debt
5,723
1,441
7,695
Deferred revenue
1,124
518
766
Other long-term liabilities
40,689
26,158
11,875
Net debt
(13,768)
(763)
351
Cash flow
Cash from operating activities
(3,583)
(4,218)
(1,485)
CAPEX
(1,552)
(2,619)
(6,082)
Cash from investing activities
(1,689)
562
(12,686)
Cash from financing activities
26,991
459
(1,966)
FCF
32,086
(12,166)
16,201
Balance
Cash
27,409
5,407
8,805
Long term investments
733
1,456
1,576
Excess cash
25,410
4,096
7,906
Stockholders' equity
(82,378)
(70,443)
(58,412)
Invested Capital
150,879
124,792
114,048
ROIC
18.31%
15.49%
ROCE
35.03%
31.02%
EV
Common stock shares outstanding
21,847
21,847
21,847
Price
Market cap
EV
EBITDA
30,177
(2,237)
22,620
EV/EBITDA
Interest
1,939
942
249
Interest/NOPBT
7.65%
1.36%